The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
The role of concomitant chemoradiotherapy versus radiation alone in T1-3N0 HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma.
复制标题
T1- 3 N 0期HPV阳性和HPV阴性口咽鳞状细胞癌同期放化疗与单纯放疗的作用
DOI：
10.1016/j.oraloncology.2022.105907
复制
发表时间：
2022-07
期刊：
影响因子：
4.8
通讯作者：
Amini, Arya
中科院分区：
文献类型：
--
作者：
Shiao, Jay C.;Holt, Douglas;Ladbury, Colton;Gao, Dexiang;Jones, Bernard;Karam, Sana D.;Amini, Arya
关键词：
评价同期放化疗(CCRT)与单纯放疗(RT)治疗T1~T3N0 HPV阳性和HPV阴性口咽鳞状细胞癌(OPSCC)的疗效。NCDB查询了2010至2017年间诊断为CT1-3N0M0 OPSCC的患者，这些患者接受了确定的RT或CCRT治疗。以OS为终点，进行单因素分析(UVA)和多变量分析(MVA)的Cox回归分析。倾向评分匹配(PSM)1：1。交互作用检验评估治疗效果的异质性。共询问了2830名患者。在MVA上，CCRT与T3N0肿瘤的OS改善相关(HR为0.49；95%CI为0.39-0.63)，但与T1N0(HR为1.43；95%CI为0.99-2.07)和T2N0(HR为0.92；95%CI为0.75-1.13)无关。对于T3患者，CCRT改善了HPV阴性(HR为0.43；95%CI为0.31-0.59)和HPV阳性肿瘤(HR为0.39；95%CI为0.25-0.61)的OS。经PSM治疗后，T1-2N0 HPV阴性肿瘤(HR 1.10；95%CI 0.85-1.43；p=0.48)和T1-2N0 HPV阳性肿瘤(HR 1.15；95%CI 0.79-1.68；p=0.45)患者的CCRT与RT无统计学差异。在PSM治疗后，对于T3N0 HPV阴性(HR 0.43；95%CI 0.31-0.59；p<；0.01)和HPV阳性肿瘤(HR 0.39；95%CI 0.25-0.61；p<；0.01)患者，CCRT改善了OS。在HPV阳性和HPV阴性的T3N0 OPSCC中，CCRT与OS的改善有关。对于HPV阴性和HPV阳性的肿瘤，单纯RT和CCRT对T1-T2N0和OPSCC的OS相似。
To evaluate the role of curative intent concurrent chemoradiation (CCRT) vs radiation (RT) alone for T1-T3N0 HPV-positive and HPV-negative oropharyngeal squamous cell cancer (OPSCC). The NCDB was queried for patients diagnosed between 2010 and 2017 with CT1-3N0M0 OPSCC treated with definitive RT or CCRT. Univariable analysis (UVA) and multivariable analysis (MVA) Cox regression analysis was performed with OS as the endpoint. Propensity score matching (PSM) 1:1 was performed. Interaction test to assess heterogeneity of treatment effect. A total of 2830 patients were queried. On MVA, CCRT was associated with improved OS for T3N0 tumors (HR 0.49; 95% CI 0.39–0.63) but not for T1N0 (HR 1.43; 95% CI 0.99–2.07) and T2N0 (HR 0.92; 95% CI 0.75–1.13). For T3 patients, CCRT improved OS for HPV-negative (HR 0.43; 95% CI 0.31–0.59) and HPV-positive tumors (HR 0.39; 95% CI 0.25–0.61). After PSM, CCRT was not statistically different to RT for patients with T1-2N0 HPV-negative tumors (HR 1.10; 95% CI 0.85–1.43; p = 0.48) and T1-2N0 HPV-positive tumors (HR 1.15; 95% CI 0.79–1.68; p = 0.45). After PSM, CCRT improved OS compared to RT alone for patients with T3N0 HPV-negative (HR 0.43; 95% CI 0.31–0.59; p < 0.01) and HPV-positive tumors (HR 0.39; 95 %CI 0.25–0.61; p < 0.01). CCRT is associated with improved OS in HPV-positive and HPV-negative T3N0 OPSCC. RT alone vs. CCRT demonstrated similar OS for T1-T2N0 OPSCC for both HPV negative and HPV positive tumors.
登录
查看更多内容
影响因子：
11.2
作者：
Kimple RJ;Smith MA;Blitzer GC;Torres AD;Martin JA;Yang RZ;Peet CR;Lorenz LD;Nickel KP;Klingelhutz AJ;Lambert PF;Harari PM
通讯作者：
Harari PM
影响因子：
168.9
作者：
Mehanna, Hisham;Robinson, Max;Dunn, Janet
通讯作者：
Dunn, Janet
影响因子：
5.7
作者：
Blanchard, Pierre;Baujat, Bertrand;Pignon, Jean-Pierre
通讯作者：
Pignon, Jean-Pierre
影响因子：
45.3
作者：
Magrini, Stefano Maria;Buglione, Michela;Grisanti, Salvatore
通讯作者：
Grisanti, Salvatore
影响因子：
51.1
作者：
Giralt, Jordi;Trigo, Jose;VanderWalde, Ari
通讯作者：
VanderWalde, Ari